Biologics in uveitis: An update
Keywords:
Biologics, uveitis, cytokines, anti-TNF alpha, managementAbstract
‘Uveitis is’ the term used to describe inflammation of the uvea. It can be due to infective or non-infective agents. Most of the non-infectious uveitides are autoimmune or auto-inflammatory in nature, and the management of non-infective uveitis is often crucial. Advancements in biotechnology and understanding the pathophysiologies of autoimmune diseases have enabled the development of the new class of drugs named ‘biologics’. These drugs act at cellular level inhibiting the actions of pro-inflammatory cytokines including tumor necrosis factor-α (TNF-α), interleukin-1, and IL-6, and B and T lymphocytes. Biologics have been proven to be less toxic and can be used in uveitic cases that are refractory to conventional therapy. Though the efficacy of biologics is based on insufficient clinical trials, majority of them indicate preferable outcomes on refractory uveitis, with remarkable promise to increase the possibility of long-term remission. In this review, we aimed to outline the ideal characteristics of each biologic drug and review the data to support the use of current and emerging biological therapies.
References
Kanski JJ, Bowling B. Clinical ophthalmology: a systematic approach. Elsevier Health Sciences; 2011.
Touhami S, Diwo E, Sève P, Trad S, Bielefeld P, Sène D, Abad S, Brézin A, Quartier P, KonéPaut I, Weber M. Expert opinion on the use of biological therapy in non-infectious uveitis. Expert opinion on biological therapy;2019.
Duica I, Voinea LM, Mitulescu C, Istrate S, Coman IC, Ciuluvica R. The use of biologic therapies in uveitis. Romanian journal of ophthalmology. 2018;62:105.
Dogra M, Singh R, Agarwal A, Sharma A, Singh SR, Gautam N, Yangzes S, Samanta R, Sharma M, Aggarwal K, Sharma A. Epidemiology of uveitis in a tertiary-care referral institute in North India. Ocular immunology and inflammation. 2017;25: S46-53.
Barisani-Asenbauer T, Maca SM, Mejdoubi L, Emminger W, Machold K, Auer H. Uveitis-a rare disease often associated with systemic diseases and infections-a systematic review of 2619 patients. Orphanet journal of rare diseases. 2012:57.
Priyanka, Biswas J. Biologicals in uveitis. Journal of Clinical Ophthalmology and Research. 2017;5:3.
McNally TW, Damato EM, Murray PI, Denniston AK, Barry RJ. An update on the use of biologic therapies in the managementof uveitis in Behçet’s disease: a comprehensive review. Orphanet journal of rare diseases. 2017 ;12:130.
Jabs DA, Rosenbaum JT, Foster CS, Holland GN, Jaffe GJ, Louie JS, Nussenblatt RB, Stiehm ER, Tessler H, Van Gelder RN, Whitcup SM. Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel. American journal of ophthalmology. 2000;130:492-513.
Shahab MA, Mir TA, Zafar S. Optimising drug therapy for non-infectious uveitis. International ophthalmology. 2018:1-8.
Adan A, Mesquida M, Llorenç V. Biologic drugs in noninfectious uveitis: an update. Expert Review of Ophthalmology. 2013 Oct 1;8(5):501-16.
Hamzaoui K, Hamzaoui A, Guemira F, Bessioud M, Hamza MH, Ayed K. Cytokine profile in Behçet’s disease patients. Scandinavian journal of rheumatology. 2002;31:205-10.
El-Asrar AM, Struyf S, Kangave D, Al-Obeidan SS, Opdenakker G, Geboes K, Van Damme J. Cytokine profiles in aqueous humor of patients with different clinical entities of endogenous uveitis. Clinical Immunology. 2011;139:177-84.
Pérez-Guijo V, Santos-Lacomba M, Sánchez-Hernández M, Castro-Villegas MD, Gallardo-Galera JM, Collantes-Estévez E. Tumour necrosis factor-alpha levels in aqueous humour and serum from patients with uveitis: the involvement of HLA-B27. Current medical research and opinion. 2004 ;20:155-7.
Lacomba MS, Martín CM, Galera JM, Vidal MA, Estévez EC, Chamond RR, Omar MM. Aqueous humor and serum tumor necrosis factor-α in clinical uveitis. Ophthalmic research. 2001;33:251-5.
Jaffe GJ, Dick AD, Brézin AP, Nguyen QD, Thorne JE, Kestelyn P, Barisani-Asenbauer T, Franco P, Heiligenhaus A, Scales D, Chu DS. Adalimumab in patients with active noninfectious uveitis. New England Journal of Medicine. 2016 ;375:932-43.
Jaffe GJ, Dick AD, Brézin AP, Nguyen QD, Thorne JE, Kestelyn P, Barisani-Asenbauer T, Franco P, Heiligenhaus A, Scales D, Chu DS. Adalimumab in patients with active noninfectious uveitis. New England Journal of Medicine. 2016 ;375:932-43.
Nguyen QD, Merrill PT, Jaffe GJ, Dick AD, Kurup SK, Sheppard J, Schlaen A, Pavesio C, Cimino L, Van Calster J, Camez AA. Adalimumab for prevention of uveitic flare in patients with inactive non-infectious uveitis controlled by corticosteroids (VISUAL II): a multicentre, double-masked, randomised, placebo-controlled phase 3 trial. The Lancet. 2016 ;388:1183-92.
Suhler EB, Lowder CY, Goldstein DA, Giles T, Lauer AK, Kurz PA, Pasadhika S, Lee ST, de Saint Sardos A, Butler NJ, Tessler HH. Adalimumab therapy for refractory uveitis: results of a multicentre, open-label, prospective trial. British Journal of Ophthalmology. 2013;97:481-6.
Rudwaleit M, Rødevand E, Holck P, Vanhoof J, Kron M, Kary S, Kupper H. Adalimumab effectively reduces the rate of anterior uveitis flares in patients with active ankylosing spondylitis: results of a prospective open-label study. Annals of the rheumatic diseases. 2009;68:696-701.
van Denderen JC, Visman IM, Nurmohamed MT, Suttorp-Schulten MS, van der Horst-Bruinsma IE. Adalimumab significantly reduces the recurrence rate of anterior uveitis in patients with ankylosing spondylitis. The Journal of rheumatology. 2014;41:1843-8.
Erckens RJ, Mostard RL, Wijnen PA, Schouten JS, Drent M. Adalimumab successful in sarcoidosis patients with refractory chronic non-infectious uveitis. Graefe’s Archive for Clinical and Experimental Ophthalmology. 2012;250:713-20.
Bawazeer A, Raffa LH, Nizamuddin. Clinical experience with adalimumab in the treatment of ocular Behçet disease. Ocular immunology and inflammation. 2010;18:226-32.
Ramanan AV, Dick AD, Jones AP, McKay A, Williamson PR, Compeyrot-Lacassagne S, Hardwick B, Hickey H, Hughes D, Woo P, Benton D. Adalimumab plus methotrexate for uveitis in juvenile idiopathic arthritis. New England Journal of Medicine. 2017;376:1637-46.
Scheinfeld N. Adalimumab: a review of side effects. Expert opinion on drug safety. 2005;4:637-41.
Suhler EB, Smith JR, Wertheim MS, Lauer AK, Kurz DE, Pickard TD, Rosenbaum JT. A prospective trial of infliximab therapy for refractory uveitis: preliminary safety and efficacy outcomes. Archives of Ophthalmology. 2005;123:903-12.
Markomichelakis N, Delicha E, Masselos S, Fragiadaki K, Kaklamanis P, Sfikakis PP. A single infliximab infusion vs corticosteroids for acute panuveitis attacks in Behçet’s disease: a comparative 4-week study. Rheumatology. 2010 Nov 20;50:593-7.
Okada AA, Goto H, Ohno S, Mochizuki M, Ocular Behcet’s Disease Research Group of Japan. Multicenter study of infliximab for refractory uveoretinitis in Behcet disease. Archives of Ophthalmology. 2012;130:592-8.
Ueda S, Akahoshi M, Takeda A, Inoue Y, Omoto A, Ayano M, Kimoto Y, Mitoma H, Arinobu Y, Niiro H, Tsukamoto H. Long-term efficacy of infliximab treatment and the predictors of treatment outcomes in patients with refractory uveitis associated with Behçet’s disease. European journal of rheumatology. 2018;5:9.
Scott LJ. Etanercept: a review of its use in autoimmune inflammatory diseases. Drugs. 2014;74:1379-410.
Brito-Zerón P, Perez-Alvarez R, Ramos-Casals M, BIOGEAS Study Group. Etanercept and uveitis: friends or foes?.
Kakkassery V, Mergler S, Pleyer U. Anti-TNF-α Treatment: A Possible Promoter in Endogenous Uveitis? Observational Report on Six Patients: Occurrence of Uveitis Following Etanercept Treatment. Current eye research. 2010;35:751-6.
Gaujoux-Viala C, Giampietro C, Gaujoux T, Ea HK, Prati C, Orcel P, Wendling D, Lioté F. Scleritis: a paradoxical effect of etanercept? Etanercept-associated inflammatory eye disease. The Journal of rheumatology. 2012;39233-9.
Fonollosa A, Artaraz J, Les I, Martinez-Berriotxoa A, Izquierdo JP, Lopez AS, Gardeazaba J, Berasategui B, Martinez-Alday N. Sarcoid intermediate uveitis following etanercept treatment: a case report and review of the literature. Ocular immunology and inflammation. 2012;20:44-8.
Foster CS, Tufail F, Waheed NK, Chu D, Miserocchi E, Baltatzis S, Vredeveld CM. Efficacy of etanercept in preventing relapse of uveitis controlled by methotrexate. Archives of ophthalmology. 2003;121:437-40.
Tahir Z, Kavanaugh A. The role of golimumab in inflammatory arthritis. A review of the evidence. Therapeutic advances in musculoskeletal disease. 2018:181-94.
Mesquida M, Victoria Hernández M, Llorenç V, Pelegrín L, Espinosa G, Dick AD, Adán A. Behçet disease-associated uveitis successfully treated with golimumab. Ocular immunology and inflammation. 2013;21:160-2.
William M, Faez S, Papaliodis GN, Lobo AM. Golimumab for the treatment of refractory juvenile idiopathic arthritis-associated uveitis. Journal of ophthalmic inflammation and infection. 2012;2:231-3.
van Bentum RE, Heslinga SC, Nurmohamed MT, Gerards AH, Griep EN, Koehorst CB, Kok MR, Schilder AM, Verhoef M, van der Horst-Bruinsma IE. Reduced Occurrence Rate of Acute Anterior Uveitis in Ankylosing Spondylitis Treated with Golimumab—The GO-EASY Study. The Journal of rheumatology. 2019;46:153-9.
Biggioggero M, Crotti C, Becciolini A, Miserocchi E, Favalli EG. The Management of Acute Anterior Uveitis Complicating Spondyloarthritis: Present and Future. BioMed research international. 2018.
Connock M, Tubeuf S, Malottki K, Uthman A, Round J, Bayliss S, Meads C, Moore D. Certolizumab pegol (CIMZIA®) for the treatment of rheumatoid arthritis. Health Technol Assess. 2010;14:1-0.
Ferrante M, Vermeire S, Rutgeerts P. Certolizumab pegol in the treatment of Crohn’s disease. Expert opinion on biological therapy. 2013;13:595-605.
Özçimen AA, Dilek K, Bingöl Ü, Sarıcaoğlu H, Sarandöl A, Taşkapılıoğlu Ö, Yurtkuran M, Yurtkuran MA, Oral HB. IL-1 cluster gene polymorphisms in Turkish patients with Behçet’s disease. International journal of immunogenetics. 2011;38:295-301.
Planck SR, Woods A, Clowers JS, Nicklin MJ, Rosenbaum JT, Rosenzweig HL. Impact of IL-1 signalling on experimental uveitis and arthritis. Annals of the rheumatic diseases. 2012;71:753-60.
Ooi KG, Galatowicz G, Calder VL, Lightman SL. Cytokines and chemokines in uveitis–Is there a correlation with clinical phenotype?. Clinical medicine & research. 2006;4:294-309.
Cantarini L, Vitale A, Scalini P, Dinarello CA, Rigante D, Franceschini R, Simonini G, Borsari G, Caso F, Lucherini OM, Frediani B. Anakinra treatment in drug-resistant Behcet’s disease: a case series. Clinical Rheumatology. 2015;34:1293-301.
Ramírez J, Cañete JD. Anakinra for the treatment of rheumatoid arthritis: a safety evaluation. Expert opinion on drug safety. 2018;17:727-32.
Teoh SC, Sharma S, Hogan A, Lee R, Ramanan AV, Dick AD. Tailoring biological treatment: anakinra treatment of posterior uveitis associated with the CINCA syndrome. British journal of ophthalmology. 2007;91:263-4.
Schiff M. Subcutaneous abatacept for the treatment of rheumatoid arthritis. Rheumatology. 2013;52:986-97.
Birolo C, Zannin ME, Arsenyeva S, Cimaz R, Miserocchi E, Dubko M, Deslandre CJ, Falcini F, Alessio M, La Torre F, Denisova E. Comparable efficacy of abatacept used as first-line or second-line biological agent for severe juvenile idiopathic arthritis-related uveitis. The Journal of rheumatology. 2016;43:2068-73.
Sadreddini S, Noshad H, Molaeefard M, Noshad R. Treatment of retinal vasculitis in Behcet’s disease with rituximab. Modern Rheumatology. 2008;18:306.
Davatchi F, Shams H, Rezaipoor M, Sadeghi abdollahiB, Shahram F, Nadji A, Chamsdavatchi c, Akhlaghi M, Faezi T, Naderi N. Rituximab in intractable ocular lesions of Behcet’s disease; randomized single blind control study (pilot study). International Journal of Rheumatic Diseases. 2010;13:246-52.
Huber JP, David Farrar J. Regulation of effector and memory T cell functions by type I interferon. Immunology. 2011;132 :466-74.
Hatemi G, Silman A, Bang D, Bodaghi B, Chamberlain AM, Gul A, Houman MH, Kötter I, Olivieri I, Salvarani C, Sfikakis PP. Management of Behçet disease: a systematic literature review for the European League Against Rheumatism evidence-based recommendations for the management of Behçet disease. Annals of the rheumatic diseases. 2009;68:1528-34.
Bodaghi B, Gendron G, Wechsler B, Terrada C, Cassoux N, Lemaitre C, Fradeau C, LeHoang P, Piette JC. Efficacy of interferon alpha in the treatment of refractory and sight threatening uveitis: a retrospective monocentric study of 45 patients. British Journal of Ophthalmology. 2007;91:335-9.
Butler NJ, Suhler EB, Rosenbaum JT. Interferon alpha 2b in the treatment of uveitic cystoid macular edema. Ocular immunology and inflammation. 2012;20:86-90.
Sleijfer S, Bannink M, Van Gool AR, Kruit WH, Stoter G. Side effects of interferon-α therapy. Pharmacy world and science. 2005;27:423.
Blech M, Peter D, Fischer P, Bauer MM, Hafner M, Zeeb M, Nar H. One target—two different binding modes: structural insights into gevokizumab and canakinumab interactions to interleukin-1β. Journal of molecular biology. 2013 Jan 9;425:94-111.
Ugurlu S, Ucar D, Seyahi E, Hatemi G, Yurdakul S. Canakinumab in a patient with juvenile Behcet’s syndrome with refractory eye disease. Annals of the Rheumatic Diseases. 2012;71:1589-91.
Fabiani C, Vitale A, Emmi G, Lopalco G, Vannozzi L, Guerriero S, Gentileschi S, Bacherini D, Franceschini R, Frediani B, Galeazzi M. Interleukin (IL)-1 inhibition with anakinra and canakinumab in Behçet’s disease-related uveitis: a multicenter retrospective observational study. Clinical rheumatology. 2017;36:191-7.
Hatemi G, Seyahi E, Fresko I, Talarico R, Hamuryudan V. One year in review 2017: Behçet’s syndrome. Clin Exp Rheumatol. 2017 Jan 1;35(Suppl 108):S3-15.
Toplak N, Blazina Š, Avčin T. The role of IL-1 inhibition in systemic juvenile idiopathic arthritis: current status and future perspectives. Drug Design, Development and Therapy. 2018;12:1633.
Gül A, Tugal-Tutkun I, Dinarello CA, Reznikov L, Esen BA, Mirza A, Scannon P, Solinger A. Interleukin-1β-regulating antibody XOMA 052 (gevokizumab) in the treatment of acute exacerbations of resistant uveitis of Behçet’s disease: an open-label pilot study. Annals of the rheumatic diseases. 2012;71:563-6.
Tugal-Tutkun I, Kadayifcilar S, Khairallah M, Lee SC, Ozdal P, Özyazgan Y, Song JH, Yu HG, Lehner V, de Cordoue A, Bernard O. Safety and efficacy of gevokizumab in patients with Behçet’s disease uveitis: results of an exploratory phase 2 study. Ocular immunology and inflammation. 2017;25:62-70.
Zhou ZY, Chen SL, Shen N, Lu Y. Cytokines and Behcet’s disease. Autoimmunity reviews. 2012;11:699-704.
Mesquida M, Molins B, Llorenç V, Hernández MV, Espinosa G, de la Maza MS, Adán A. Twenty-four month follow-up of tocilizumab therapy for refractory uveitis-related macular edema. Retina. 2018;38:1361-70.
Yokota S, Imagawa T, Mori M, Miyamae T, Aihara Y, Takei S, Iwata N, Umebayashi H, Murata T, Miyoshi M, Tomiita M. Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial. The Lancet. 2008;371:998-1006.
Calvo Río V, Santos Gómez M, Calvo I, González‐Fernández MI, López Montesinos B, Mesquida M, Adán A, Hernández MV, Maíz O, Atanes A, Bravo B. Anti–Interleukin 6 Receptor Tocilizumab for Severe Juvenile Idiopathic Arthritis–Associated Uveitis Refractory to Anti–Tumor Necrosis Factor Therapy: A Multicenter Study of TwentyFive Patients. Arthritis & Rheumatology. 2017;69:668-75.
Kolls JK, Lindén A. Interleukin-17 family members and inflammation. Immunity. 2004;21:467-76.
Xu S, Cao X. Interleukin-17 and its expanding biological functions. Cellular & molecular immunology. 2010;7:164.
Dick AD, Tugal-Tutkun I, Foster S, Zierhut M, Liew SM, Bezlyak V, Androudi S. Secukinumab in the treatment of noninfectious uveitis: results of three randomized, controlled clinical trials. Ophthalmology. 2013;120:777-87.
Sota J, Rigante D, Lopalco G, Frediani B, Franceschini R, Galeazzi M, Iannone F, Tosi GM, Fabiani C, Cantarini L. Biological therapies for the treatment of Behçet’s disease-related uveitis beyond TNF-alpha blockade: a narrative review. Rheumatology international. 2018;38:25-35.
Lamb YN, Duggan ST. Ustekinumab: a review in moderate to severe Crohn’s disease. Drugs. 2017;77:1105-14.
Caso F, Costa L, Rigante D, Lucherini OM, Caso P, Bascherini V, Frediani B, Cimaz R, Marrani E, Nieves-Martín L, Atteno M. Biological treatments in Behçet’s disease: beyond anti-TNF therapy. Mediators of inflammation. 2014.
Riera R, Porfírio GJ, Torloni MR. Alemtuzumab for multiple sclerosis. Cochrane Database of Systematic Reviews. 2016.
Pasadhika S, Rosenbaum JT. Update on the use of systemic biologic agents in the treatment of noninfectious uveitis. Biologics: targets & therapy. 2014; 8:67.
Yap YC, Papathomas T, Kamal A. Results of intravitreal dexamethasone implant 0.7 mg (Ozurdex®) in non infectious posterior uveitis. Int J Ophthalmol 2015;8:835 8
Markomichelakis N, Delicha E, Masselos S, Sfikakis PP. Intravitreal infliximab for sight threatening relapsing uveitis in Behçet disease: A pilot study in 15 patients. Am J Ophthalmol 2012;154:534 41
Hamza MM, Macky TA, Sidky MK, Ragab G, Soliman MM. INTRAVITREAL INFLIXIMAB IN REFRACTORY UVEITIS IN BEHCET’S DISEASE: A Safety and Efficacy Clinical Study. Retina. 2016;36:2399-408.
Hamam RN, Barikian AW, Antonios RS, Abdulaal MR, Alameddine RM, El Mollayess G, Mansour AM. Intravitreal adalimumab in active noninfectious uveitis: a pilot study. Ocular immunology and inflammation. 2016 May 3;24(3):319-26.
Gallego-Pinazo R, Dolz-Marco R, Martínez-Castillo S, Fernando Arevalo J, Díaz-Llopis M. Update on the principles and novel local and systemic therapies for the treatment of non-infectious uveitis. Inflammation & Allergy-Drug Targets. 2013;12:38-45.
